Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad.

[1]  William M. Lee,et al.  Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  H. Janssen,et al.  PS-056-Higher relapse and retreatment rates in patients who started as HBeAg positive than negative after stopping long-term nucleos (t) ide analogue therapy: results from the randomized controlled STOP study , 2019, Journal of Hepatology.

[3]  William M. Lee,et al.  Distinct phenotype and function of circulating Vδ1+ and Vδ2+ γδT-cells in acute and chronic hepatitis B , 2019, PLoS pathogens.

[4]  M. Suarez‐Almazor,et al.  Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. , 2019, JCO clinical cancer informatics.

[5]  A. Lok,et al.  Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long‐term Treatment With Tumor Necrosis Factor Antagonists , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  E. Rigopoulou,et al.  Correction: DARING-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B , 2018, Antiviral therapy.

[7]  E. Rigopoulou,et al.  DARING-B: Discontinuation of Effective Entecavir or Tenofovir Disoproxil Fumarate Long-Term Therapy before HBsAg Loss in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B , 2018, Antiviral therapy.

[8]  M. Sugiyama,et al.  Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients. , 2018, JCI insight.

[9]  Leo Swadling,et al.  Circulating and intrahepatic antiviral B cells are defective in hepatitis B , 2018, The Journal of clinical investigation.

[10]  E. Newell,et al.  PD-1 blockade partially recovers dysfunctional virus–specific B cells in chronic hepatitis B infection , 2018, The Journal of clinical investigation.

[11]  T. Berg,et al.  Less can be more: A finite treatment approach for HBeAg‐negative chronic hepatitis B , 2018, Hepatology.

[12]  Y. Liaw,et al.  Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B , 2018, Hepatology.

[13]  M. Manns,et al.  Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients , 2018, The Journal of infectious diseases.

[14]  V. Barili,et al.  Strategies to overcome HBV-specific T cell exhaustion: checkpoint inhibitors and metabolic re-programming. , 2018, Current opinion in virology.

[15]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[16]  Ding‐Shinn Chen,et al.  Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy , 2018, The Journal of infectious diseases.

[17]  I. Colle,et al.  Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes , 2018, Alimentary pharmacology & therapeutics.

[18]  P. Belperio,et al.  Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. , 2018, The lancet. Gastroenterology & hepatology.

[19]  M. Suarez‐Almazor,et al.  Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Tseng,et al.  Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation , 2018, The Journal of clinical investigation.

[21]  M. Nguyen,et al.  Serum Aminotransferase Flares in Pregnant and Postpartum Women With Current or Prior Treatment for Chronic Hepatitis B , 2017, Journal of clinical gastroenterology.

[22]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.

[23]  T. Berg,et al.  Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. , 2017, Journal of hepatology.

[24]  M. Buti,et al.  The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B , 2017, Hepatology.

[25]  Martín Prieto,et al.  Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study , 2017, PloS one.

[26]  R. D. de Knegt,et al.  Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[28]  K. Chayama,et al.  Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages , 2017, Hepatology.

[29]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[30]  Kyong‐Mi Chang,et al.  Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology. , 2016, Clinics in liver disease.

[31]  Kyong‐Mi Chang,et al.  Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. , 2016, Current opinion in pharmacology.

[32]  O. Akbari,et al.  Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission. , 2016, Immunity.

[33]  P. Marcellin,et al.  Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). , 2016, Journal of hepatology.

[34]  William M. Lee,et al.  Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. , 2016, Gastroenterology.

[35]  M. Sugiyama,et al.  Indoleamine‐2,3‐dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B , 2016, Hepatology.

[36]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[37]  Linda V. Sinclair,et al.  Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells , 2015, Nature Medicine.

[38]  A. Barbo,et al.  Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases , 2015, Journal of viral hepatitis.

[39]  A. Bertoletti,et al.  Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections , 2015, Hepatology.

[40]  Y. Falck‐Ytter,et al.  American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy , 2014 .

[41]  Tongyu Lin,et al.  Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. , 2014, JAMA.

[42]  S. Lewin,et al.  Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B , 2014, Gut.

[43]  F. Luciani,et al.  Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations , 2014, Journal of viral hepatitis.

[44]  H. Patton,et al.  Management of hepatitis B during pregnancy , 2014, Nature Reviews Gastroenterology &Hepatology.

[45]  S. Locarnini,et al.  Anti‐viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post‐partum flare , 2014, Alimentary pharmacology & therapeutics.

[46]  H. Chan,et al.  Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. , 2014, Gastroenterology.

[47]  H. Janssen,et al.  Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: Is the glass half full or half empty? , 2013, Hepatology.

[48]  Shou-Dong Lee,et al.  Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  C. Pan,et al.  Antiviral Therapy for Chronic Hepatitis B in Pregnancy , 2013, Seminars in Liver Disease.

[50]  P. Marcellin,et al.  739 ALT FLARES DURING TREATMENT WITH PEGINTERFERON LAMBDA OR PEGINTERFERON alfa IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B INFECTION (CHB) , 2013 .

[51]  G. Reynolds,et al.  Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion , 2013, The Journal of experimental medicine.

[52]  L. Scobie,et al.  Hepatitis E: source and route of infection, clinical manifestations and new developments , 2013, Journal of viral hepatitis.

[53]  S. Bae,et al.  Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. , 2013, Clinical and experimental rheumatology.

[54]  P. Lampertico,et al.  Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. , 2012, Gastroenterology.

[55]  Kelvin K. W. Chan,et al.  Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  D. Vassilopoulos,et al.  Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. , 2012, Gastroenterology.

[57]  M. Buti,et al.  Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis , 2012, Gut.

[58]  A. Bertoletti,et al.  Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection , 2011, Gut.

[59]  Wei Zhao,et al.  A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. , 2011, Journal of hepatology.

[60]  Jiyuan Zhang,et al.  Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients , 2011, Hepatology.

[61]  F. Chisari,et al.  Pathogenesis of hepatitis B virus infection. , 2010, Pathologie-biologie.

[62]  R. Simon,et al.  B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus–associated acute liver failure , 2010, Proceedings of the National Academy of Sciences.

[63]  Antonio Bertoletti,et al.  A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. , 2010, Journal of hepatology.

[64]  Hung‐Chih Yang,et al.  Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double‐blind, placebo‐controlled study , 2009, Journal of viral hepatitis.

[65]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.

[66]  G. Alexander,et al.  Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection , 2008, The Journal of experimental medicine.

[67]  J. Hoofnagle,et al.  Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy , 2008, Annals of Internal Medicine.

[68]  C. Hsiung,et al.  A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: A randomized trial , 2008, Hepatology.

[69]  R. D. de Man,et al.  Exacerbation of chronic hepatitis B infection after delivery , 2007, Journal of viral hepatitis.

[70]  P. Borrow,et al.  Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage , 2007, The Journal of experimental medicine.

[71]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[72]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[73]  Wen-Yih Wu,et al.  Hepatitis B post‐partum e antigen clearance in hepatitis B carrier mothers: Correlation with viral characteristics , 2006, Journal of gastroenterology and hepatology.

[74]  C. Chu,et al.  Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. , 2005, Journal of hepatology.

[75]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[76]  R. D. de Man,et al.  Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy , 2005, Gut.

[77]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[78]  D. Fong,et al.  Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. , 2003, Gastroenterology.

[79]  A. Bertoletti,et al.  Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. , 2003, Journal of hepatology.

[80]  M. Avelino,et al.  Pregnancy as a risk factor for acute toxoplasmosis seroconversion. , 2003, European journal of obstetrics, gynecology, and reproductive biology.

[81]  F. Chisari,et al.  Interleukin-18 Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice , 2002, Journal of Virology.

[82]  H. Chiou,et al.  Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B , 2002, Hepatology.

[83]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[84]  S. Nair,et al.  Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? , 2001, Hepatology.

[85]  L. Simonsen,et al.  Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. , 1998, American journal of epidemiology.

[86]  R. Williams,et al.  Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. , 1997, The Journal of clinical investigation.

[87]  F. Chisari,et al.  Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways , 1994, Journal of virology.

[88]  E. Christensen,et al.  Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study , 1994 .

[89]  F. Chisari,et al.  Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis , 1993, The Journal of experimental medicine.

[90]  R. D. de Man,et al.  Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. , 1992, Gastroenterology.

[91]  Keegan Jm,et al.  Parenteral and oral acyclovir for management of varicella pneumonia in pregnancy: a case report with review of literature. , 1991 .

[92]  H. R. Gordon,et al.  Parenteral and oral acyclovir for management of varicella pneumonia in pregnancy: a case report with review of literature. , 1991, The West Virginia medical journal.

[93]  A. Lok,et al.  Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. , 1990, Journal of hepatology.

[94]  Ding‐Shinn Chen,et al.  Postpartum subsidence of hepatitis B viral replication in hbeag‐positive carrier mothers , 1989, Journal of medical virology.

[95]  C. Chu,et al.  Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody‐positive patients , 1987, Hepatology.

[96]  C. Chu,et al.  Acute exacerbation in hepatitis B e antigen positive chronic type B hepatitis. A clinicopathological study. , 1985, Journal of hepatology.

[97]  J. Hoofnagle,et al.  Spontaneous reactivation of chronic hepatitis B virus infection. , 1984, Gastroenterology.

[98]  C. Chu,et al.  [Chronic hepatitis in Taiwan. II. A clinical and laboratory study (author's transl)]. , 1981, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association.